Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis

Autor: Taylor, P, Keystone, E, Ortmann, R, Issa, M, Xie, L, Muram, D, Bradley, J, De Bono, S, Rooney, T, Tanaka, Y, Faraawi, R

Publikováno v: 45. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 31. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 27. Jahrestagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20170906-20170909; Stuttgart; DOCRA.28 /20170904/

Background: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor for the treatment of patients (pts) with moderate to severe rheumatoid arthritis (RA). The objective of this analysis was to evaluate efficacy and safety in pts from RA-BEAM who switched f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a5be0180643c157780129be891144b3
https://doi.org/10.3899/jrheum.170256

Efficacy and safety of switching from adalimumab to baricitinib: long-term data from phase 3 extension study in patients with rheumatoid arthritis

Autor: Weinblatt, M, Taylor, P, Keystone, E, Ortmann, R, Issa, M, Xie, L, de Bono, S, Tanaka, Y

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::4f3387f001c960aa0d00ec3bc9958cc3
https://doi.org/10.1002/art.40700

LOW RATES OF RADIOGRAPHIC PROGRESSION OF STRUCTURAL JOINT DAMAGE OVER 2 YEARS OF BARICITINIB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS

Autor: Heijde, D. van der, Schiff, M., Tanaka, Y., Klar, R., Xie, L., Meszaros, G., Ishii, T., Casillas, M., Ortmann, R., Emery, P.

Publikováno v: Annals of the Rheumatic Diseases, 76, 510-511

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::20a68ab74efc2c3160b38eebc5e7ce2e
http://hdl.handle.net/1887/116185

Structural Elucidation of a New Puzzling Compound Emerged from Doebner Quinoline Synthesis.

Autor: Al-Matarneh, Cristina Maria¹ (AUTHOR) almatarneh.cristina@icmpp.ro, Nicolescu, Alina² (AUTHOR) alina@icmpp.ro

Publikováno v: Molbank. Sep2024, Vol. 2024 Issue 3, pM1841. 11p.

EFFICACY AND SAFETY OF TABALUMAB, AN ANTI-B CELL ACTIVATING FACTOR MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAD AN INADEQUATE RESPONSE TO TNF-ALPHA INHIBITORS: RESULTS FROM A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY

Autor: Schiff, M., Combe, B., Dorner, T., Kremer, J.M., Huizinga, T.W., Veenhuizen, M., Gill, A., Zou, H., Komocsar, W., Berclaz, P.Y., Ortmann, R., Lee, C.

Publikováno v: Annals of the Rheumatic Diseases, 73, 952-953

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3a6a1776ff4c9993a6a03455fe6ef5c8
https://hdl.handle.net/1887/101707